Advertisement

Genetic testing in sudden unexpected natural death in the young: New York City Office of Chief Medical Examiner’s experience and perspective

  • Yingying Tang
  • Nori Williams
  • Barbara A. Sampson
Commentary

Abstract

Postmortem genetic testing is a diagnostic tool that is becoming increasingly utilized. The benefits and limitations of genetic testing in cases of sudden, unexpected death in the young (≤ 40 years old) are reviewed from the perspective of the Office of Chief Medical Examiner of the City of New York, whose Molecular Genetics Laboratory, accredited by College of American Pathologists, has had 15 years of postmortem testing experience. Challenges to the interpretation and communication of testing results are highlighted, and opportunities for improving testing yield are discussed for age groups across the lifespan, from infancy to adulthood.

Keywords

Postmortem Genetic testing Sudden death 

Notes

Funding

Grant awards (2015-DN-BX-K017 and 2014-DN-BX-K001) by National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.

Compliance with ethical standards

Review article (no identifiable information is used).

Conflict of interest

None.

Ethical approval

Office of Chief Medical Examiner of the City of New York approved this work.

Informed consent

Review article (no identifiable information is used).

References

  1. 1.
    Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths. Forensic Sci Int. 2014;237:90–9.CrossRefGoogle Scholar
  2. 2.
    Lin Y, Williams N, Wang D, et al. Applying high-resolution variant classification to cardiac arrhythmogenic gene testing in a demographically diverse cohort of sudden unexplained deaths. Circ Cardiovasc Genet. 2017;10(6).  https://doi.org/10.1161/CIRCGENETICS.117.001839
  3. 3.
    Duncan JR, Paterson DS, Hoffman JM, et al. Brainstem serotonergic deficiency in sudden infant death syndrome. JAMA. 2010;303:430–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Haynes RL, Frelinger AL 3rd, Giles EK, et al. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017;114:7695–700.CrossRefPubMedGoogle Scholar
  5. 5.
    Sadeh D, Shannon DC, Abboud S, Saul JP, Akselrod S, Cohen RJ. Altered cardiac repolarization in some victims of sudden infant death syndrome. N Engl J Med. 1987;317:1501–5.CrossRefGoogle Scholar
  6. 6.
    Perticone F, Ceravolo R, Maio R, Cosco C, Mattioli PL. Heart rate variability and sudden infant death syndrome. Pacing Clin Electrophysiol. 1990;13:2096–9.CrossRefGoogle Scholar
  7. 7.
    Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med. 1998;338:1709–14.CrossRefGoogle Scholar
  8. 8.
    Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15:186–9.CrossRefGoogle Scholar
  9. 9.
    Gando I, Morganstein J, Jana K, McDonald TV, Tang Y, Coetzee WA. Infant sudden death: Mutations responsible for impaired Nav1.5 channel trafficking and function. Pacing Clin Electrophysiol. 2017;40:703–12.CrossRefGoogle Scholar
  10. 10.
    Tester DJ, Wong LCH, Chanana P, et al. Exome-wide rare variant analyses in sudden infant death syndrome. J Pediatr. 2018;203:423–8 e11.CrossRefGoogle Scholar
  11. 11.
    Mates J, Mademont-Soler I, Del Olmo B, et al. Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. Eur J Hum Genet. 2018;26:1014–25.CrossRefGoogle Scholar
  12. 12.
    Yoshinaga M, Kucho Y, Ushinohama H, Ishikawa Y, Ohno S, Ogata H. Autonomic function and QT interval during night-time sleep in infant long QT syndrome. Circ J. 2018;82:2152–9.CrossRefGoogle Scholar
  13. 13.
    Weintraub RG, Gow RM, Wilkinson JL. The congenital long QT syndromes in childhood. J Am Coll Cardiol. 1990;16:674–80.CrossRefGoogle Scholar
  14. 14.
    Georgievskaya Z, Tang Y, Williams N, Sampson B, Gelb BD, Kontorovich AR. Fatal myocarditis is associated with rare cardiomyopathy gene variants. Circulation. 2018;136:A18206.Google Scholar
  15. 15.
    Tang Y, Sampson B, Pack S, et al. Ethnic differences in out-of-hospital fatal pulmonary embolism. Circulation. 2011;123:2219–25.CrossRefGoogle Scholar
  16. 16.
    Halvorsen M, Lin Y, Sampson BA, et al. Whole exome sequencing reveals severe thrombophilia in acute unprovoked idiopathic fatal pulmonary embolism. EBioMedicine. 2017;17:95–100.CrossRefPubMedGoogle Scholar
  17. 17.
    Gago-Diaz M, Ramos-Luis E, Zoppis S, et al. Postmortem genetic testing should be recommended in sudden cardiac death cases due to thoracic aortic dissection. Int J Legal Med. 2017;131:1211–9.CrossRefGoogle Scholar
  18. 18.
    Chen J, Weber M, Um SY, Walsh CA, Tang Y, McDonald TV. A dual mechanism for I (Ks) current reduction by the pathogenic mutation KCNQ1-S277L. Pacing Clin Electrophysiol. 2011;34:1652–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36:1162–4.CrossRefGoogle Scholar
  20. 20.
    Williams N, Marion R, McDonald TV, et al. Phenotypic variations in carriers of predicted protein-truncating genetic variants in MYBPC3: an autopsy-based case series. Cardiovasc Pathol. 2018;37:30–3.CrossRefGoogle Scholar
  21. 21.
    Sampson BA, Tang Y. Holistic approach to determine cause of autopsy-negative sudden natural death. J Am Coll Cardiol. 2017;69:2146–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Molecular Genetics LaboratoryOffice of Chief Medical ExaminerNew YorkUSA
  2. 2.Forensic Pathology DepartmentOffice of Chief Medical ExaminerNew YorkUSA

Personalised recommendations